Kyle Carpenter, DO
Neurocritical Care · Kansas City, MONPI 1962713081
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.1% of the total across 201 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 9.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,692 and has fallen 98.3% since, to $28 in 2024.
Across 201 payments — averaging $13.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$267
- AbbVie$262
- Avanir Pharmaceuticals, Inc.$253
- Novartis$219
- EMD Serono, Inc.$207
- Sanofi$193
- plus $1K from 29 others
What the payments were for
- Speaking & faculty fees$1355%
- Food & beverage$2,64095%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 23 | $267 |
| AbbVie(2 entities) | 20 | $262 |
| Avanir Pharmaceuticals, Inc. | 36 | $253 |
| Novartis | 15 | $219 |
| EMD Serono, Inc. | 16 | $207 |
| Sanofi | 10 | $193 |
| UCB, Inc. | 10 | $139 |
| Acorda Therapeutics, Inc | 6 | $135 |
| AstraZeneca | 6 | $131 |
| Teva Pharmaceuticals USA, Inc. | 7 | $114 |
| Upsher-smith Laboratories LLC | 4 | $75 |
| Portola Pharmaceuticals, LLC | 3 | $64 |
| CSL Behring | 3 | $64 |
| Acadia Pharmaceuticals Inc | 4 | $56 |
| SK Life Science, Inc. | 2 | $55 |
| Lundbeck LLC | 4 | $55 |
| Eisai Inc. | 3 | $55 |
| Amgen | 3 | $55 |
| Boston Scientific | 4 | $48 |
| GE HealthCare | 2 | $35 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $31 |
| Neurocrine Biosciences, Inc. | 2 | $29 |
| Hospira, Inc. | 2 | $28 |
| Johnson & Johnson | 2 | $27 |
| Lilly USA, LLC | 2 | $25 |
| Jazz Pharmaceuticals Inc. | 1 | $23 |
| Livanova USA, Inc. | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| Harmony Biosciences LLC | 1 | $15 |
| Ipsen Biopharmaceuticals, Inc | 1 | $14 |
| Aquestive Therapeutics, Inc. | 1 | $14 |
| Amneal Pharmaceuticals LLC | 1 | $13 |
| Zyla Life Sciences, Inc. | 1 | $13 |
| Mallinckrodt Hospital Products Inc. | 1 | $13 |
| MDD US Operations, LLC | 1 | $12 |
How this compares
Too few neurocritical care providers in Missourito place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Amitriptyline Hcl | 32 | $422 |
| ClopidogrelClopidogrel Bisulfate | 17 | $187 |
| Duloxetine Hcl | 11 | $154 |
| Gabapentin | 15 | $140 |
| Atorvastatin Calcium | 16 | $67 |
Paid to pharmacies, not to this prescriber.
Other neurocritical care in Kansas City
- Premkumar Nattanmai ChandrasekaranColumbia$66K
- Francisco GomezColumbia$1K
- Niraj AroraColumbia$365
- Asher AlbertsonSaint Louis$330
- Baback ArshiSaint Louis$293
- Rameez MerchantColumbia$132
- Peter KangSaint Louis$85
- Casey DunnSaint Louis$70
- Philip SunSaint Louis$31
- Randika ParakramaweeraSaint Louis$15
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.